Category: 3. Business

Tokyo – July 1, 2025 – Blackstone (NYSE:BX) today announces a key senior leadership appointment in Japan, as the firm continues to expand its footprint in the market and strengthen its commitment to Japan.
 
Muneya Taniguchi will join as Vice Chairman of Japan and Executive Advisor to lead the firm’s expansion, primarily focusing on western Japan. Prior to Blackstone, he was with MUFG Bank as Deputy President and with Mitsubishi UFJ Morgan Stanley Securities as Deputy Chairman, building relationships and guiding business strategies in western Japan.
 
Atsuhiko Sakamoto, Head of Private Equity, Blackstone Japan, said: “We are pleased to welcome industry veteran Muneya to our Blackstone Japan team. His expertise will be invaluable as we continue to expand our presence in the market and stay differentiated through our scale and partnerships. We are coming on the heels of our most active year in Japan across businesses, investing in fantastic businesses and assets and delivering for investors.”
 
He continued: “Japan is an integral part of Blackstone’s global business and a key driver of our growth. We wouldn’t be where we are today without the support of our Japanese partners and investors – some who have entrusted us since our founding days 40 years ago.”
 
Blackstone has executed a number of high-profile transactions in the country, including investing in Tokyo Garden Terrace Kioicho, the largest real estate investment by a foreign investor; Amutus (formerly Infocom), the leading provider of digital comics; Sony Payment Services, carveout of Sony’s payment service provider; I’rom, a preeminent Japanese site management organization; and CMIC, Japan’s top contract research organization. In Private Wealth, the firm has been a pioneer, partnering with leading Japanese financial institutions to create access to its four flagship strategies to individual investors.
 
About Blackstone
Blackstone is the world’s largest alternative asset manager. Blackstone seeks to deliver compelling returns for institutional and individual investors by strengthening the companies in which the firm invests. Blackstone’s $1.2 trillion in assets under management include global investment strategies focused on real estate, private equity, credit, infrastructure, life sciences, growth equity, secondaries and hedge funds. Further information is available at www.blackstone.com. Follow @blackstone on LinkedIn, X (Twitter), and Instagram. 
 
Contact
Mariko Sanchanta
[email protected]
+852 9012 5314
 
Kekst CNC
[email protected]
090-3239-9348

SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) — Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025. Sarepta is a commercial-stage biopharmaceutical company that focuses on RNA and gene therapies for the treatment of rare diseases. During the class period, Sarepta was engaged in the development of therapies to treat Duchenne muscular dystrophy (“Duchenne”), including ELEVIDYS. ELEVIDYS is a prescription gene therapy intended for a limited category of people with Duchenne.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

The Allegations: Robbins LLP is Investigating Allegations that Sarepta Therapeutics, Inc. (SRPT) Mislead Investors Regarding the Safety its ELEVIDYS Drug

According to the complaint, during the class period, defendants failed to disclose that: (i) ELEVIDYS posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; and (iii) the severity of adverse events from ELEVIDYS treatment would cause the Company to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy’s present and expanded approvals.

Plaintiff alleges that on March 18, 2025, Sarepta issued a safety update on ELEVIDYS announcing that a patient had died following treatment with ELEVIDYS. On this news, Sarepta’s stock price fell $27.81 per share, or 27.44%, to close at $73.54 per share on March 18, 2025. Then, on June 15, 2025, Sarepta disclosed a second patient had died of acute liver failure following treatment with ELEVIDYS. The Company announced it was suspending shipments of ELEVIDYS for non-ambulatory patients while Sarepta took time to evaluate trial regimens and discussed findings with regulatory authorities. Sarepta also revealed that it was pausing dosing in one of its ELEVIDYS clinical studies. On this news, Sarepta’s stock price fell $15.24 per share, or 42.12%, to close at $20.91 per share on June 15, 2025.

Finally, on June 24, 2025, the FDA announced it was investigating the risk of acute liver failure with serious outcomes following treatment with ELEVIDYS. On this nes, Sarepta’s stock price fell $1.52 per share, or 8.01%, to close at $17.46 per share on June 25, 2025.

What Now: You may be eligible to participate in the class action against Sarepta Therapeutics, Inc. Shareholders who want to serve as lead plaintiff for the class must file a motion for lead plaintiff by August 25, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.  

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against Sarepta Therapeutics, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

And as PYMNTS reported last month, Apollo Global Management is working with five banks, including JPMorgan Chase & Co. and Goldman Sachs Group, to trade private credit.

As the lines blur in financial services, and traditional banking players link with nonbanks to expand credit, so too is there a blurring of the nomenclature of those efforts, referred to variously as shadow banking or nonbank financial intermediation.

Data found in this Monday (June 30) post by the St. Louis Federal Reserve underscore the magnitude of exposure. As measured at the end of the first quarter of 2025, U.S. banks held $1.14 trillion in loans outstanding to the nonbank financial sector.

“This interconnectedness between banks and nonbanks adds an extra layer of intermediation, as banks lend to mortgage companies, insurance companies, investment funds (such as mutual funds, money market funds, hedge funds and private capital funds), pension funds, broker-dealers, securitization vehicles and other financial entities, which then lend directly to end users in the economy,” noted the Fed. The growth rate of non-depository financial institutional lending has grown by 26% on average each year since 2012.

Getting a bit more granular, the Financial Stability Board estimated late last year that the aggregate FinTech lending across seven jurisdictions came in at $38.5 billion.

As the FSB elaborated, “FinTech lending platforms can act as auxiliaries or intermediaries. As auxiliaries, they can be in the form of a ‘marketplace platform,’ which is an online market that allows lenders to trade directly with borrowers (peer-to-peer lending and crowdfunding platforms). Fintech lending platforms can act as intermediaries when they use their balance sheets to originate the lending.”

Loans to mortgage and private credit intermediaries each represent 23% of loans outstanding, and loans to business intermediaries and consumer intermediaries represent 21% and 9%, respectively, estimated the Fed.

Risks of ‘Runnable’ Activity

In separate data and analysis as of last week, according to a report by the Congressional Research Service, “banks are increasingly lending to NBFIs (nonbank financial institutions) and, at the same time, reducing their lending to commercial and industrial borrowers.”

“Increased lending from banks to NBFIs could expose banks to counterparty credit risk and spillover effects during a financial crisis…” the report added. “The size and growth of NBFI suggest that significant amount of financing is being intermediated and held outside of the banking sector. In contrast to the traditional banking model, where banks normally manage risks (e.g., credit, market, liquidity, and operational risks) on their balance sheets, the market-based NBFI financing model shifts risks toward capital markets investors and intermediaries.”

As for the risks, the CRS cautioned that the “vulnerabilities affecting financial stability are present in capital markets NBFI, including in certain money-like instruments that face potential ‘runs,’ leverage levels, interconnectedness between nonbanks and banks, data and transparency issues, liquidity mismatch at certain open-end funds, and concentration risk at market intermediaries.”

There’s a knock-on effect here, as some financial institutions are grappling with shadow banking stalwarts as competitors, which in turn has shifted activities away from core deposits toward long-term securities and other holdings. In this paper from economists at the Fed and at the University of Houston, there’s the contention that in doing so, net interest income margins are pressured.